A 66-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer

home / case-based-peer-perspectives / a-66-year-old-man-with-metastatic-castrate-sensitive-prostate-cancer

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

Case Impressions: 66-Year-Old Man With mCSPC

EP. 1: Case Impressions: 66-Year-Old Man With mCSPC

Ralph V. Boccia, MD
December 2nd 2020

Watch

Frontline Therapy for mCSPC

EP. 2: Frontline Therapy for mCSPC

Ralph V. Boccia, MD
December 2nd 2020

Watch

mCSPC: Patient Variables and Treatment Selection

EP. 3: mCSPC: Patient Variables and Treatment Selection

Ralph V. Boccia, MD
December 2nd 2020

Watch

The TITAN Trial in mCSPC

EP. 4: The TITAN Trial in mCSPC

Ralph V. Boccia, MD
December 2nd 2020

Watch

AR-Targeted Therapy for mCSPC: Adverse Events

EP. 5: AR-Targeted Therapy for mCSPC: Adverse Events

Ralph V. Boccia, MD
December 2nd 2020

Watch

AR-Targeted Therapy for mCSPC: Monitoring for Progression

EP. 6: AR-Targeted Therapy for mCSPC: Monitoring for Progression

Ralph V. Boccia, MD
December 2nd 2020

Watch

mCSPC: Incorporating Newer Therapies Into Practice

EP. 7: mCSPC: Incorporating Newer Therapies Into Practice

Ralph V. Boccia, MD
December 2nd 2020

Watch